Literature DB >> 11551635

Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210.

E G Hankins1, D C Warhurst, C H Sibley.   

Abstract

We have expressed dhfr alleles of Plasmodium falciparum in the budding yeast, Saccharomyces cerevisiae, and used this yeast model to identify single amino acid substitutions that confer high level pyrimethamine resistance on the background of the triple mutant dhfr (I51+R59+N108). Mutations in three clusters were identified: codons 50-57, 187-193, and 213-214. Several mutations previously identified in field samples were also isolated, including codons 50 and 164. The I164L mutation is of particular interest, because the quadruple mutant genotype (N51I+C59R+S108N+I164L) encodes an enzyme that is no longer inhibited by pyrimethamine, rendering sulfadoxine/pyrimethamine (SP; Fansidar) clinically ineffective. Thirty-six novel alleles were tested to determine their sensitivity to chlorcycloguanil and WR99210, two DHFR inhibitors that are in clinical and pre-clinical development, respectively. Chlorcycloguanil is effective against parasites that carry the triple mutant allele, but in vitro analysis has suggested that chlorcycloguanil will be clinically ineffective against parasites that carry the quadruple mutant allele of dhfr. In our screen, 23 of 36 novel strains were as resistant to chlorcycloguanil as the quadruple mutant, and one strain was 10-fold more resistant. WR99210 is still effective in the nM range against parasites that carry the quadruple mutant allele. In the preliminary screen, 31 of 36 novel alleles were as sensitive to WR99210 as the quadruple mutant. Detailed analysis of the remaining five showed that four of the five had IC(50) values in the same range as the quadruple mutant, and one, N51I+C59R+S108N+E192G, had an IC(50) value about fivefold higher. This result suggests that WR99210 and related compounds will be clinically effective against quadruple mutants currently found in Southeast Asia and South America and against most novel alleles that could be selected on the background of the triple mutant genotype now prevalent in East Africa.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551635     DOI: 10.1016/s0166-6851(01)00335-8

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  14 in total

Review 1.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 2.  Winning the arms race by improving drug discovery against mutating targets.

Authors:  Amy C Anderson
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

3.  Scalable, Continuous Evolution of Genes at Mutation Rates above Genomic Error Thresholds.

Authors:  Arjun Ravikumar; Garri A Arzumanyan; Muaeen K A Obadi; Alex A Javanpour; Chang C Liu
Journal:  Cell       Date:  2018-11-08       Impact factor: 41.582

4.  Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system.

Authors:  Michele D Hastings; Jason D Maguire; Michael J Bangs; Peter A Zimmerman; John C Reeder; J Kevin Baird; Carol Hopkins Sibley
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 5.  Targeting purine and pyrimidine metabolism in human apicomplexan parasites.

Authors:  John E Hyde
Journal:  Curr Drug Targets       Date:  2007-01       Impact factor: 3.465

6.  Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.

Authors:  Deanpen Japrung; Ubolsree Leartsakulpanich; Sudsanguan Chusacultanachai; Yongyuth Yuthavong
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

7.  Secondary mutations correct fitness defects in Toxoplasma gondii with dinitroaniline resistance mutations.

Authors:  Christopher Ma; Johnson Tran; Catherine Li; Lakshmi Ganesan; David Wood; Naomi Morrissette
Journal:  Genetics       Date:  2008-09-09       Impact factor: 4.562

Review 8.  Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.

Authors:  Philip J Peters; Michael C Thigpen; Monica E Parise; Robert D Newman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 9.  Antifolate resistance in Africa and the 164-dollar question.

Authors:  John E Hyde
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-04       Impact factor: 2.184

10.  Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.

Authors:  Michele D Hastings; Carol Hopkins Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.